Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination. Continue your routine care with us by scheduling an in-person appointment or Video Visit.

Longitudinal change in magnetic susceptibility of new enhanced multiple sclerosis (MS) lesions measured on serial quantitative susceptibility mapping (QSM).

TitleLongitudinal change in magnetic susceptibility of new enhanced multiple sclerosis (MS) lesions measured on serial quantitative susceptibility mapping (QSM).
Publication TypeJournal Article
Year of Publication2016
AuthorsZhang Y, Gauthier SA, Gupta A, Comunale J, Chiang GChia-Yi, Zhou D, Chen W, Giambrone AE, Zhu W, Wang Y
JournalJ Magn Reson Imaging
Volume44
Issue2
Pagination426-32
Date Published2016 08
ISSN1522-2586
KeywordsAdult, Aging, Algorithms, Brain, Disease Progression, Early Diagnosis, Female, Humans, Image Enhancement, Image Interpretation, Computer-Assisted, Imaging, Three-Dimensional, Longitudinal Studies, Magnetic Fields, Male, Multiple Sclerosis, Reproducibility of Results, Sensitivity and Specificity, Subtraction Technique
Abstract

PURPOSE: To measure the longitudinal change in multiple sclerosis (MS) lesion susceptibility using quantitative susceptibility mapping (QSM).

MATERIALS AND METHODS: The study was approved by our Institutional Review Board. Longitudinal changes in quantitative susceptibility values of new enhanced-with-Gd MS lesions were measured at baseline magnetic resonance imaging (MRI) and on a follow-up MRI in 29 patients within 2 years using a 3D multiple echo gradient echo sequence on a 3T scanner. Paired t-test and the generalized estimating equations (GEE) model was used to analyze the longitudinal change.

RESULTS: Lesion susceptibility values relative to normal-appearing white matter (NAWM) changed from 3.61 ± 6.11 ppb when enhanced-with-Gd at the baseline MRI to 20.42 ± 10.23 ppb when not-enhanced-with-Gd at the follow-up MRI (P < 0.001).

CONCLUSION: MS lesion susceptibility value increases significantly as the lesion evolves from enhanced-with-Gd to not-enhanced-with-Gd, serving as a disease biomarker. J. Magn. Reson. Imaging 2016;44:426-432.

DOI10.1002/jmri.25144
Alternate JournalJ Magn Reson Imaging
PubMed ID26800367
PubMed Central IDPMC4946979
Grant ListR01 EB013443 / EB / NIBIB NIH HHS / United States
R01 NS090464 / NS / NINDS NIH HHS / United States
S10 RR025145 / RR / NCRR NIH HHS / United States

Weill Cornell Medicine Neurology 525 E. 68th St.
PO Box 117
New York, NY 10065 Phone: (212) 746-6575